According to researchers, 25 percent of all cancer patients use medical marijuana. Cancer patients are finding relief from medical cannabis. And they want to know more about it. Research conducted at St. George’s University of London, found the two most common cannabinoids in marijuana, tetrahydrocannabinol (THC) and cannabidiol (CBD), weakened the ferocity of cancer cells and made them more susceptible to radiation treatment. Other studies have shown that medical marijuana treatments can slow the growth of cancer cells and halt their spread to other parts of the body.
Another Israeli group postulated that the anti-inflammatory and immunosuppressive effects of CBD might make it a valuable adjunct in the treatment of acute graft-versus-host disease (GVHD) in patients who have undergone allogeneic hematopoietic stem cell transplantation. The authors investigated CBD 300 mg/d in addition to standard GVHD prophylaxis in 48 adult patients who had undergone transplantation predominantly for acute leukemia or myelodysplastic syndrome (NCT01385124 and NCT01596075). The combination of CBD with standard GVHD prophylaxis was found to be safe. Compared with 101 historical controls treated with standard prophylaxis, patients who received CBD appeared to have a lower incidence of grade II to grade IV GVHD, suggesting that a randomized controlled trial (RCT) is warranted.
A mixture of fiberglass, hemp fiber, kenaf, and flax has been used since 2002 to make composite panels for automobiles. The choice of which bast fiber to use is primarily based on cost and availability. Various car makers are beginning to use hemp in their cars, including Audi, BMW, Ford, GM, Chrysler, Honda, Iveco, Lotus, Mercedes, Mitsubishi, Porsche, Saturn, Volkswagen and Volvo. For example, the Lotus Eco Elise and the Mercedes C-Class both contain hemp (up to 20 kg in each car in the case of the latter).
Cannabis contains a seemingly unique class of chemicals, the cannabinoids, of which more than 60 have been described, but only a few are psychoactive. Cannabinoids are produced in specialized epidermal glands, which differ notably in distribution on different organs of the plant (high concentrations occur on the upper surface of the young leaves and young twigs, on the tepals, stamens, and especially on the perigonal bract). Given this distribution, the glands would seem to be protective of young and reproductive above-ground tissues (the roots lack glands). Two classes of epidermal glands occur—stalked and sessile (Fig. 8), but in either case the glandular cells are covered by a sheath under which resin is accumulated, until the sheath ruptures, releasing resin on the surface. The resin is a sticky mixture of cannabinoids and a variety of terpenes. The characteristic odor of the plant is due to the abundant terpenes, which are not psychoactive. The more important cannabinoids are shown in Fig. 9. In the plant the cannabinoids exist predominantly in the form of carboxylic acids, which decarboxylate with time or when heated. Delta-9-tetrahydrocannabinol (D9-THC, or simply THC) is the predominant psychoactive component. Other THC isomers also occur, particularly D8-THC, which is also psychoactive. Technically, the euphoric psychological effects of THC are best described by the word psychotomimetic. Cannabidiol (CBD) is the chief non-psychotomimetic cannabinoid. A THC concentration in marijuana of approximately 0.9% has been suggested as a practical minimum level to achieve the (illegal) intoxicant effect, but CBD (the predominant cannabinoid of fiber and oilseed varieties) antagonizes (i.e. reduces) the effects of THC (Grotenhermen and Karus 1998). Concentrations of 0.3% to 0.9% are considered to have “only a small drug potential” (Grotenhermen and Karus 1998). Some cannabinoid races have been described, notably containing cannabichromene (particularly in high-THC forms) and cannabigerol monomethyl ether (in some Asian strains). The biosynthetic pathways of the cannabinoids are not yet satisfactorily elucidated, although the scheme shown in Fig. 10 is commonly accepted. At least in some strains, THC is derived from cannabigerol, while in others it may be derived from CBD. CBN and D8-THC are considered to be degradation products or analytical artifacts (Pate 1998a).
APPLICATIONS ARE NOW AVAILABLE for the 2019 Industrial Hemp Research Pilot Program. You can access the Grower Application Packet, the Processor/Handler Application Packet, and the University/College Affiliation Application Packet on the Program Page titled "Applications for the Hemp Program" in the right side bar (or scroll further down on mobile devices) or through the green link in the description below. Complete instructions and guidelines for applicants are contained in the application packets. Grower applications are due November 30, 2018 at 4:30 PM Eastern Time.
Some manufacturers ship CBD products nationally, an illegal action which the FDA has not enforced in 2018, with CBD remaining as the subject of an FDA investigational new drug evaluation and is not considered legal as a dietary supplement or food ingredient as of November 2018. CBD is openly sold in head shops and health food stores in some states where such sales have not been explicitly legalized.
Cannabinoids, terpenoids, and other compounds are secreted by glandular trichomes that occur most abundantly on the floral calyxes and bracts of female plants. As a drug it usually comes in the form of dried flower buds (marijuana), resin (hashish), or various extracts collectively known as hashish oil. In the early 20th century, it became illegal in most of the world to cultivate or possess Cannabis for sale or personal use.
Medical marijuana in the U.S. is controlled at the state level. Per federal law, cannabis is illegal as noted in the Controlled Substances Act, but the federal government has stated they will not actively prosecute patients and caregivers complying with state medical marijuana laws. However, use of medical marijuana outside of the state laws for illegal use or trafficking will not be tolerated by state or federal government.
Hemp has at times in the past been grown simply for its ornamental value. The short, strongly-branched cultivar ‘Panorama’ (Fig. 43) bred by Iván Bósca, the dean of the world’s living hemp breeders, was commercialized in Hungary in the 1980s, and has been said to be the only ornamental hemp cultivar available. It has had limited success, of course, because there are very few circumstances that permit private gardeners can grow Cannabis as an ornamental today. By contrast, beautiful ornamental cultivars of opium poppy are widely cultivated in home gardens across North America, despite their absolute illegality and the potentially draconian penalties that could be imposed. Doubtless in the unlikely event that it became possible, many would grow hemp as an ornamental.
In 1937, the Marijuana Tax Act strictly regulated the cultivation and sale of all cannabis varieties. The Controlled Substances Act of 1970 classified all forms of cannabis — including hemp — as a Schedule I drug, making it illegal to grow it in the United States (which is why we’re forced to import hemp from other countries as long as it contains scant levels of THC — 0.3% is the regulation for hemp cultivation in the European Union and Canada). As a result of this long-term prohibition, most people have forgotten the industrial uses of the plant and continue to misidentify hemp with its cannabis cousin, marijuana.
The U.S. Department of Agriculture (USDA) prohibits discrimination in all its programs and activities on the basis of race, color, national origin, gender, religion, age, disability, political beliefs, sexual orientation, and marital or family status. (Not all prohibited bases apply to all programs.) Many materials can be made available in alternative formats for ADA clients. To file a complaint of discrimination, write USDA, Office of Civil Rights, Room 326-W, Whitten Building, 14th and Independence Avenue, SW, Washington, DC 20250-9410 or call 202-720-5964.
Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.